CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2026, and reviewed recent business highlights. “During the first half of 2026, we continued to meaningfully advance our business, generating over $1 billion in quarterly product revenues fo...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer's Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases...
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo's analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map®, the industry's most compr...
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region.
The index added two companies on Friday, but more are likely to be added in the near future.